ARCHIVES

Sorafenib Targets AML Driven By Mutant FLT3 Gene

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013

DCT To Examine Groups’ Studies, Directions, Role in 2000 A.D. Goal

June 8, 1984

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009

Appropriators Ask What Happens After NIH Budget-Doubling Ends In FY2004.

May 25, 2001

In Brief: Bresnick Directs Norris Cotton Cancer Center; FASEB Honors Kirschstein; Van Nevel’s 2th Year

February 5, 1993

Obituary: Joseph Burchenal, 93, A Leader In Cancer Drug Development at MSKCC.

March 17, 2006